Abstract _ Full Text (HTML) _ Full Text (PDF)

Case report

Cancer Research Frontiers. 2016 Feb; 2(1): 126-130. doi: 10.17980/2016.126

Polyserositis in the course of chronic myelomonocytic leukemia: impact of hypomethylating agents.

 

Segolène Rémy-Néris1,2, Lise Willems1,2, Bénédicte Deau1,2, Sylvain Pilorge1,2, Marielle Legoff1,2, Patricia Franchi1,2, Aurélie lefevre2,3, Christine Lorut2,3, Kim Blanc2,3, Antoine Rabbat2,3, Nicolas Dupin2,4, Marco Alifano2,5, Didier Bouscary1,2  and Jerome Tamburini1,2,#

1Hematology Department, Cochin Hospital, Assistance Publique – Hôpitaux de Paris (AP-HP), 75014 Paris 

2Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, 75005 Paris

3Respiratory Intensive Care Unit, Cochin Hospital, AP-HP, 75014 Paris 

4Dermatology Department, Cochin Hospital, AP-HP, 75014 Paris 

5Thoracic Surgery Department, Cochin Hospital, AP-HP, 75014 Paris, France 

 

*Corresponding author: Service d’Hématologie Clinique, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris, France. Email: jerome.tamburini@aphp.fr, phone: +33158412121, fax: +33184106322.

Citation: Segolène Rémy-Néris, et al. Polyserositis in the course of chronic myelomonocytic leukemia: impact of hypomethylating agents. Cancer Research Frontiers. 2016 Feb; 2(1): 126-130. doi: 10.17980/2016.126

Copyright: @ 2016 Segolène Rémy-Néris, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors declare no competing financial interests.

Received Dec 7, 2015; Revised Feb 19, 2016; Accepted Mar 10, 2015. Published Mar 24, 2016

 

Abstract

Chronic myelomonocytic leukemia (CMML) is a rare myelodysplastic/myeloproliferative neoplasm (MDS/MPN) disorder with frequent extra-hematopoietic manifestations. CMML-related serositis is due to leukemic involvement, autoimmune manifestations or both. Serositis is correlated to adverse outcome in the course of CMML in small case-series reported before the introduction of hypomethylating agents into the clinical practice. We report a favorable evolution of 3 patients with CMML and polyserositis treated by Azacytidine.

Key words: CMML, Azacytidine, hypomethylating agents, serositis, cardiac tamponade

 

 

 

 

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann